Phase III trial of darolutamide in patients with non-metastatic castration-resistant prostate cancer meets primary endpoint (for specialized target groups only)

The safety and tolerability observed in the trial were consistent with previously published data on darolutamide
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news